# Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

> **NCT04070040** · PHASE2 · RECRUITING · sponsor: **Beijing Sanbo Brain Hospital** · enrollment: 21 (estimated)

## Conditions studied

- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Camrelizumab

## Key facts

- **NCT ID:** NCT04070040
- **Lead sponsor:** Beijing Sanbo Brain Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-02-13
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2024-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04070040

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04070040, "Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04070040. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*